Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome

Shibamiya, Asuka; Ohwada, Chikako; Ishii, Arata; Mishina, Tatsuzo; Nagai, Yurie; Hino, Yutaro; Kayamori, Kensuke; Oshima-Hasegawa, Nagisa; Muto, Tomoya; Tsukamoto, Shokichi; Takeda, Yusuke; Mitsukawa, Shio; Mimura, Naoya; Iseki, Tohru; Misawa, Sonoko; Kuwabara, Satoshi; Nakaseko, Chiaki; Sakaida, Emiko

doi:10.1038/s41409-020-01024-9

Cited by 8 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirm results reported by Shibamiya and colleagues [10]: a second ASCT is an effective treatment option for POEMS patients relapsing after a first ASCT. A second exposure to high-dose melphalan seems to be well-tolerated and produces a good response, without more neurotoxic drugs, in patients with significant neurological impairment [11].…”

Section: Discussionsupporting

confidence: 92%

“…The Shibamiya study [10] described relapses within one year from a first ASCT; in our cases relapses were late, and in keeping with previous studies [6,12,13]. The median interval from the first ASCT to the second was 40 months (range, 21-125 months) in Shibamiya [10] and 91 months in ours.…”

Section: Discussionsupporting

confidence: 89%

“…In previous studies the incidence of complications associated with ASCT in patients with POEMS syndrome was found to be associated with age and comorbidities [13][14][15]; therefore, a correct re-evaluation of relapsed patients in terms of fitness for ASCT needs to be done. The median age at second ASCT was comparable in Shabamiya's study [10] and in our two patients, as well as our data in terms of low rates of toxicity. We decided to perform a second ASCT in patients with an aggressive, but melphalan chemosensitive, POEMS.…”

Section: Discussionsupporting

confidence: 88%

“…We want to describe our experience with two patients who underwent a second ASCT for late disease progression after the first ASCT in comparison to a previous published case series of four patients successfully treated with ASCT after a brief progression [10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome

et al. 2022

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is a good option in fit young patients affected by POEMS syndrome. Few data are published on how to treat these patients in case of relapse. In this paper we described our two patients who underwent a second ASCT. From our experience, we can confirm that a second transplant is a real treatment option with good results and limited side effects. It provided excellent response and long-term disease-free survival in POEMS patients who relapsed after a first transplant, including late relapses.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Thus, they are distinctly advantaged as being acceptable to all patients and widely used in clinical trials [3,[12][13][14]. The therapeutic effect and safe use of ESCs and iPSCs are increasingly validated in the treatment of multiple diseases such as myocardial infarction, spinal cord injury, and macular degeneration [15][16][17][18][19][20]. In addition to being useful tools for treating disease, stem cells are useful tools for learning about disease as well.…”

Section: Introductionmentioning

confidence: 99%

Stem Cell-Based Disease Modeling and Cell Therapy

Bai

2020

Cells

View full text Add to dashboard Cite

Stem cell science is among the fastest moving fields in biology, with many highly promising directions for translatability. To centralize and contextualize some of the latest developments, this Special Issue presents state-of-the-art research of adult stem cells, induced pluripotent stem cells (iPSCs), and embryonic stem cells as well as cancer stem cells. The studies we include describe efficient differentiation protocols of generation of chondrocytes, adipocytes, and neurons, maturation of iPSC-derived cardiomyocytes and neurons, dynamic characterization of iPSC-derived 3D cerebral organoids, CRISPR/Cas9 genome editing, and non-viral minicircle vector-based gene modification of stem cells. Different applications of stem cells in disease modeling are described as well. This volume also highlights the most recent developments and applications of stem cells in basic science research and disease treatments.

show abstract

POEMS Syndrome—Clinical Picture and Management. Current Knowledge

Jurczyszyn¹,

Olszewska-Szopa²

2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome

Cited by 8 publications

References 11 publications

Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome

Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome

Stem Cell-Based Disease Modeling and Cell Therapy

POEMS Syndrome—Clinical Picture and Management. Current Knowledge

Contact Info

Product

Resources

About